Cambridge, MA · Founded 2017 · Privately Held (backing)
Developer of brain-penetrant and peripherally-restricted small molecules designed to slow or modify the progression of neurodegenerative and cardiorenal diseases. Eikonizo Therapeutics is based in Cambridge, MA and was founded in 2017. It was valued at $54 million at its later-stage round in Dec 2023, the last priced event on record. It has raised $46.1 million across 2 recorded rounds; the latest was a $371,352 seed round in May 2018.
These 8 firms already write checks for companies like Eikonizo Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.